For research use only. Not for therapeutic Use.
Dehydroemetine（Cat No.:I017169）is a semisynthetic derivative of emetine, primarily used as an antiprotozoal agent for the treatment of amoebiasis. It works by inhibiting protein synthesis in Entamoeba histolytica, disrupting parasite growth and replication. Compared to emetine, dehydroemetine has a similar mechanism of action but with reduced toxicity, making it a safer alternative for clinical use. It is administered as a second-line treatment when metronidazole is contraindicated or ineffective. Dehydroemetine’s potent activity and improved safety profile make it a valuable tool in managing severe protozoal infections.
| Catalog Number | I017169 |
| CAS Number | 4914-30-1 |
| Molecular Formula | C₂₉H₃₈N₂O₄ |
| Purity | ≥95% |
| Target | Parasite |
| IUPAC Name | (11bS)-2-[[(1R)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]-3-ethyl-9,10-dimethoxy-4,6,7,11b-tetrahydro-1H-benzo[a]quinolizine |
| InChI | InChI=1S/C29H38N2O4/c1-6-18-17-31-10-8-20-14-27(33-3)29(35-5)16-23(20)25(31)12-21(18)11-24-22-15-28(34-4)26(32-2)13-19(22)7-9-30-24/h13-16,24-25,30H,6-12,17H2,1-5H3/t24-,25+/m1/s1 |
| InChIKey | XXLZPUYGHQWHRN-RPBOFIJWSA-N |
| SMILES | CCC1=C(C[C@H]2C3=CC(=C(C=C3CCN2C1)OC)OC)C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC |
| Reference | [1]. Fouarge M, et al.Development of dehydroemetine nanoparticles for the treatment of visceral leishmaniasis.J Microencapsul. 1989 Jan-Mar;6(1):29-34. |
